SpliSense

Developing transformative RNA-based treatments for unmet needs relating to diverse pulmonary diseases.

Health Tech & Life Sciences
Active
Series B Jerusalem, Israel Founded 2016
Last updated 2026-06-18
Total raised
$43.0M
Last: Series B 2021-05
Stage
Series B
Founded
2016
Headcount
13
HQ
Jerusalem, Israel
Sector
Health Tech & Life Sciences

About

SpliSense is a clinical-stage biopharmaceutical company focused on transformative RNA-based treatments for pulmonary diseases. The company's pioneering platform harnesses Antisense Oligonucleotides (ASOs) to target the root cause of genetic mutations and modulate protein expression and function. SpliSense's lead candidate, SPL84, is an inhaled ASO therapy for cystic fibrosis patients with the 3849+10kb C→T mutation, currently in Phase 2b clinical trials.

Funding history · 5 rounds · $43.0M total

2026-06
2024-04
2018-11
Seed Round $1.0M
2017-01

Q&A

What is SpliSense's primary focus?
SpliSense is a clinical-stage biopharmaceutical company focused on developing transformative RNA-based treatments for pulmonary diseases, particularly using Antisense Oligonucleotides (ASOs).
When was SpliSense founded and where is it headquartered?
SpliSense was founded in 2016 and is headquartered in Jerusalem, Israel.
What is SpliSense's lead product candidate?
SpliSense's lead candidate is SPL84, an inhaled ASO therapy for cystic fibrosis patients with the 3849+10kb C→T mutation, which is currently in Phase 2b clinical trials.
What was SpliSense's most recent funding round?
SpliSense received a Grant in April 2024, amounting to $8,500,000, from the Cystic Fibrosis Foundation.
Which investors participated in SpliSense's Series B round?
SpliSense's Series B round in May 2021, which raised $28,500,000, included investments from OrbiMed and the Cystic Fibrosis Foundation.
Who is the CEO of SpliSense?
Gili Hart serves as the CEO of SpliSense.
How many employees does SpliSense have?
SpliSense has 11-50 employees.
What is the total amount of funding SpliSense has raised to date?
SpliSense has raised a total of $43,000,000.

Team · 7

Batsheva Kerem
Founder · Co-founder & CSO
CBO
Asaf Cohen
VP CMC
Head of Research
LinkedIn ↗
Chairman

Sectors & technology

Primary sector
Health Tech & Life Sciences
Technologies
Target customers
Business model
B2B

Highlights

Patents

Tags

medical-technologiespharma-companiespharmaceuticalsbiotechnologydrug-developmenttreatmentsgeneticsrna-based-therapiesantisense-oligonucleotidescystic-fibrosispulmonary-diseases
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)

External links

Websitesplisense.com/
LinkedInlinkedin.com/company/77849119

Identifiers & details

Founded2016
Employees (exact)13

Radar intelligence

Patents

EPO9

Publications (Crossref)

Works3

Web history (Wayback)

Domainsplisense.com

Certificate / subdomain footprint

Subdomains2